Accueil › Cancer du sein › Arizona › Phoenix
Essais cliniques pour Cancer du sein à Phoenix, AZ
25 études pour Cancer du sein recherchent des participants dans et autour de Phoenix (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Cancer Center at Saint Joseph's, Phoenix
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Recrutement en coursPhase 2
- Mayo Clinic Hospital, Phoenix
PRE-ISPY Phase I/II Oncology Platform Program
Recrutement en coursPhase 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Recrutement en coursPhase 3
- Mayo Clinic Cancer Center ( Site 0034), Phoenix
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Recrutement en coursPhase 3
- Ironwood Cancer & Research Centers, Phoenix
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Recrutement en coursPhase 2
- Mayo Clinic Building-Phoenix, Phoenix
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Recrutement en cours
- Mayo Clinic Arizona, Phoenix
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Recrutement en coursPhase 3
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Recrutement en coursPhase 2
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Recrutement en coursPhase 3
- Banner University Medical Center - Phoenix Campus (Banner Good Samaritan Medical Center), Phoenix
Breast Cancer, Reasoning, and Activity Intervention
Recrutement en cours
- Mayo Clinic in Arizona, Phoenix
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Recrutement en coursPhase 3
- The Dignity Health Cancer Institute, Phoenix
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Recrutement en coursPhase 3
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Recrutement en coursPhase 3
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Recrutement en coursPhase 3
- Mayo Clinic Hospital in Arizona, Phoenix
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Recrutement en coursPhase 1/2
- USOR HonorHealth, Phoenix
E-Mindfulness Approaches for Living After Breast Cancer
Recrutement en coursPhase 3
- Mayo Clinic Hospital in Arizona, Phoenix
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Recrutement en coursPhase 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Recrutement en coursPhase 3
- Ironwood Cancer & Research Centers, Phoenix
The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors
Recrutement en cours
- Arizona State University, Phoenix
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Recrutement en coursPhase 3
- Cancer Center at Saint Joseph's, Phoenix
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Recrutement en coursPhase 1/2
- Mayo Clinic, Phoenix
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Recrutement en coursÉtude observationnelle
- Cancer Center at Saint Joseph's, Phoenix
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Vincere Cancer Center, Phoenix
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recrutement en coursÉtude observationnelle
- Arizona Oncology Associates, PC, Phoenix
Essais pour Cancer du sein dans d'autres villes
- New York City, NY134 études
- Houston, TX126 études
- Boston, MA111 études
- Nashville, TN80 études
- Los Angeles, CA72 études
- Edison, NJ68 études
- St. Louis, MO64 études
- Durham, NC63 études
- Queens, NY63 études
- Chicago, IL58 études
- Philadelphia, PA56 études
- Dallas, TX55 études
Autres études à Phoenix
- Cancer colorectal25 études
- Obésité22 études
- Cancer du poumon non à petites cellules20 études
- Cancer métastatique20 études
- Insuffisance cardiaque18 études
- Cancer de la prostate17 études
- Cancer (tous types)17 études
- Myélome multiple16 études
- Cancer du pancréas16 études
- Maladie cardiovasculaire16 études
- Maladie d'Alzheimer15 études
- Surpoids15 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.